ETC-216 for coronary artery disease

Stephen J. Nicholls, Kiyoko Uno, Yu Kataoka, Steven E. Nissen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Introduction: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-IMilano (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. Areas covered: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. Expert opinion: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.

LanguageEnglish
Pages387-394
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume11
Issue number3
DOIs
Publication statusPublished - 1 Mar 2011

Keywords

  • apoA-I
  • atherosclerosis
  • high-density lipoprotein
  • risk factors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Nicholls, S. J., Uno, K., Kataoka, Y., & Nissen, S. E. (2011). ETC-216 for coronary artery disease. Expert Opinion on Biological Therapy, 11(3), 387-394. https://doi.org/10.1517/14712598.2011.557061